Status:
COMPLETED
PET Guided Bone Marrow Biopsy vs Trephine Bone Marrow Biopsy
Lead Sponsor:
Post Graduate Institute of Medical Education and Research, Chandigarh
Conditions:
Lymphoma
Bone Marrow Neoplasm
Eligibility:
All Genders
18-80 years
Brief Summary
Newly diagnosed lymphoma patients were recruited for FDG PET/CT and PET/CT guided bone marrow biopsy. All the patients also underwent routine bone marrow sampling from the posterior superior iliac spi...
Detailed Description
Newly diagnosed patients underwent FDG PET/CT for whole-body staging. All the PET/CT images were analyzed by a qualified nuclear medicine physician. The bone marrow FDG uptake was classified as negati...
Eligibility Criteria
Inclusion
- Newly diagnosed cases of lymphoma (both HL and NHL).
- Hypermetabolic bone marrow lesions on staging 18F-FDG PET/CT, which are accessible for biopsy.
- Aged between 18 -80 years.
- Informed consent prior to the procedure.
Exclusion
- Previously treated/relapsed lymphoma.
- Initiation of therapy (chemotherapy, radiation therapy) and/or hematopoietic growth factor injections before 18F-FDG PET/CT or BMTB.
- Patients who underwent a prior BMTB to evaluate the role of BMI.
- Patients with pre-existing bleeding diatheses like hemophilia, coagulopathy, INR \> 1.2 and platelet counts \< 50,000/mm3,
- Patients who refuse to provide informed consent.
- No 18F FDG avid skeletal lesions.
- Pregnant/Lactating female patients.
- Non-cooperative patients.
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2019
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT05251168
Start Date
January 1 2017
End Date
March 31 2019
Last Update
February 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nuclear Medicine, PGIMER
Chandigarh, Chandigarh, India, 160012